Wong, S.T. et al. A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat. Neurosci. 5, 1302-1308

Division of Neurobiology, Department of Molecular and Cell Biology, University of California, Berkeley, California 94720, USA.
Nature Neuroscience (Impact Factor: 14.98). 01/2003; 5(12):1302-8. DOI: 10.1038/nn975
Source: PubMed

ABSTRACT Myelin-associated glycoprotein (MAG), an inhibitor of axon regeneration, binds with high affinity to the Nogo-66 receptor (NgR). Here we report that the p75 neurotrophin receptor (p75(NTR)) is a co-receptor of NgR for MAG signaling. In cultured human embryonic kidney (HEK) cells expressing NgR, p75(NTR) was required for MAG-induced intracellular Ca2+ elevation. Co-immunoprecipitation showed an association of NgR with p75(NTR) that can be disrupted by an antibody against p75(NTR) (NGFR5), and extensive coexpression was observed in the developing rat nervous system. Furthermore, NGFR5 abolished MAG-induced repulsive turning of Xenopus axonal growth cones and Ca2+ elevation, both in neurons and in NgR/p75(NTR)-expressing HEK cells. Thus we conclude that p75(NTR) is a co-receptor of NgR for MAG signaling and a potential therapeutic target for promoting nerve regeneration.

Download full-text


Available from: John R Henley, Aug 31, 2015
  • Source
    • "The adult mammalian central nervous system (CNS) cannot be repaired spontaneously after injury. The lack of regenerative capacity in the mammalian CNS is partly due to the myelin-associated proteins including Nogo-A1, myelin-associated glycoprotein23 and oligodendrocyte myelin glycoprotein45. Nogo-66 receptor 1 (NgR1) is a common receptor for the myelin-associated inhibitors of the regeneration (i.e., Nogo-A, myelin-associated glycoprotein and oligodendrocyte myelin glycoprotein)6, as well as chondroitin sulphate proteoglycans7. Inhibition of NgR activation with neutralising antibodies against Nogo-A8, a peptide mimicking NgR1-binding region of Nogo-A (NEP1-40)9 or the ecto-domain part of NgR1 (NgR1(310) ecto-Fc)10, can promote functional recovery of the spinal cord after traumatic injury. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inhibition of Nogo-66 receptor (NgR) can promote recovery following spinal cord injury. The ecto-domain of NgR can be phosphorylated by protein kinase A (PKA), which blocks activation of the receptor. Here, we found that infusion of PKA plus ATP into the damaged spinal cord can promote recovery of locomotor function. While significant elongation of cortical-spinal axons was not detectable even in the rats showing enhanced recovery, neuronal precursor cells were observed in the region where PKA plus ATP were directly applied. NgR1 was expressed in neural stem/progenitor cells (NSPs) derived from the adult spinal cord. Both an NgR1 antagonist NEP1-40 and ecto-domain phosphorylation of NgR1 promote neuronal cell production of the NSPs, in vitro. Thus, inhibition of NgR1 in NSPs can promote neuronal cell production, which could contribute to the enhanced recovery of locomotor function following infusion of PKA and ATP.
    Scientific Reports 05/2014; 4:4972. DOI:10.1038/srep04972 · 5.58 Impact Factor
  • Source
    • "Nogo-66 is a 66 amino acid domain that, together with flanking hydrophobic regions, is a component of the RTN homology domain in the C-terminus of all Nogo isoforms [6]. Nogo-66 collapse-inducing activity is associated with high-affinity binding to its receptors NgR1 [7], [8], which forms a complex with the transmembrane proteins LINGO1, and p75 or TROY [1], [9]–[11]. Nogo-66 can also bind to the paired immunoglobulin-like receptor PirB [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The protein Nogo-A regulates axon growth in the developing and mature nervous system, and this is carried out by two distinct domains in the protein, Nogo-A-Δ20 and Nogo-66. The differences in the signalling pathways engaged in axon growth cones by these domains are not well characterized, and have been investigated in this study. We analyzed growth cone collapse induced by the Nogo-A domains Nogo-A-Δ20 and Nogo-66 using explanted chick dorsal root ganglion neurons growing on laminin/poly-lysine substratum. Collapse induced by purified Nogo-A-Δ20 peptide is dependent on protein synthesis whereas that induced by Nogo-66 peptide is not. Nogo-A-Δ20-induced collapse is accompanied by a protein synthesis-dependent rise in RhoA expression in the growth cone, but is unaffected by proteasomal catalytic site inhibition. Conversely Nogo-66-induced collapse is inhibited ∼50% by proteasomal catalytic site inhibition. Growth cone collapse induced by the Nogo-A domains Nogo-A-Δ20 and Nogo-66 is mediated by signalling pathways with distinguishable characteristics concerning their dependence on protein synthesis and proteasomal function.
    PLoS ONE 01/2014; 9(1):e86820. DOI:10.1371/journal.pone.0086820 · 3.23 Impact Factor
  • Source
    • "Interactions between trk receptors and voltage-gated potassium channels or NMDA receptors have been described [20,21]. The p75NTR can act as a co-receptor for the Nogo receptor that is known to inhibit axonal growth by interactions with MAG protein [22,23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS) with unknown etiology. It was recently suggested that autoimmunity, which had long been considered to be destructive in MS, might also play a protective role in the CNS of MS patients. Neurotrophins are polypeptides belonging to the neurotrophic factor family. While neurotrophins mediate cell survival and proliferation in the nervous system, they are also expressed within peripheral blood mononuclear cells fraction (PBMCs) of immunological system. In MS additional neurotrophic support from PBMCs might compensate relative neurotrophins deficiency in the damaged CNS tissue that needs to be repaired. Failure to produce the adequate neurotrophins concentrations might result in decreased protection of the CNS, consequently leading to increased atrophy, which is the main determinant of MS patients' end-point disability. There are several lines of evidence, both from clinical research and animal models, suggesting that neurotrophins play a pivotal role in neuroprotective and neuroregenerative processes that are often defective in the course of MS. It seems that neuroprotective strategies might be used as potentially valuable add-on therapies, alongside traditional immunomodulatory treatment in multiple sclerosis.
    International Journal of Molecular Sciences 12/2012; 13(10):13713-25. DOI:10.3390/ijms131013713 · 2.86 Impact Factor
Show more